Results 91 to 100 of about 8,174 (197)

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 14, Issue 6, Page 461-471, June 2025.
Abstract A combination of nucleotide hepatitis C virus (HCV) nonstructural protein (NS) 5B and 5A inhibitors is a preferred standard of care for treating chronic HCV. Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against HCV NS5B.
Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond   +7 more
wiley   +1 more source

A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.

PLoS Pathogens, 2014
Widely used chemical genetic screens have greatly facilitated the identification of many antiviral agents. However, the regions of interaction and inhibitory mechanisms of many therapeutic candidates have yet to be elucidated.
Hangfei Qi, C Anders Olson, Nicholas C Wu, Ruian Ke, Claude Loverdo, Virginia Chu, Shawna Truong, Roland Remenyi, Zugen Chen, Yushen Du, Sheng-Yao Su, Laith Q Al-Mawsawi, Ting-Ting Wu, Shu-Hua Chen, Chung-Yen Lin, Weidong Zhong, James O Lloyd-Smith, Ren Sun   +17 more
doaj   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Pharmacotherapy for Cirrhosis in Japan

Portal Hypertension &Cirrhosis, Volume 4, Issue 2, Page 111-119, June 2025.
As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley   +1 more source

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study

Cogent Medicine, 2020
Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study. Objectives: To identify patient characteristics associated with routine
Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier, Joerg Petersen   +12 more
doaj   +1 more source

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma:a systematic review and meta-analysis [PDF]

, 2018
Background: The influence of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus on the risk of hepatocellular carcinoma (HCC) is conflicting.
Akuta, Alonso, ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr, Cabibbo, Calleja, Cheung, Conti, Dfr, Eletreby, Grandhe, Hagiwara, Jakobsen, Kanwal, Kobayashi, Kolly, Kozbial, Lacombe, Li, Maan, Nagata, Ogata, Ouzzani, Piroth, Reddy, Reig, Rodríguez-Osorio, Terrault, Torres, Virlogeux, Waziry, Wei, Zavaglia   +31 more
core   +1 more source

Daclatasvir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia, DE SANTIS, Adriano, GINANNI CORRADINI, Stefano, Lattanzi, Barbara, Lupo1, Marinella, Maria Galluzzo, Clementina, Mennini, Gianluca, Merli, Manuela, Michelini, Zuleika, Palmisano, Lucia, Rossi, Massimo   +10 more
core   +1 more source